Publicacións en colaboración con investigadores/as de Hospital Universitario La Paz (15)

2024

  1. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

    American Journal of Hematology

  2. Women with Gaucher Disease

    Biomedicines, Vol. 12, Núm. 3

2022

  1. Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era

    Annals of Hematology, Vol. 101, Núm. 1, pp. 59-67

  2. Novel Therapies to Address Unmet Needs in ITP

    Pharmaceuticals, Vol. 15, Núm. 7

  3. Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura

    Medicina Clinica, Vol. 158, Núm. 12, pp. 630.e1-630.e14

2021

  1. Incidence and clinical profile of venous thromboembolism in hospitalized COVID-19 patients from Madrid region

    Thrombosis research, Vol. 203, pp. 93-100

  2. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573

2020

  1. Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 4, pp. 651-658

2017

  1. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

    International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516

  2. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970

2016

  1. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

    European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302

  2. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation

    European Journal of Haematology, Vol. 96, Núm. 5, pp. 483-491

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

  2. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia

    Platelets, Vol. 26, Núm. 1, pp. 83-86

  3. Use of eltrombopag after romiplostim in primary immune thrombocytopenia

    British Journal of Haematology, Vol. 169, Núm. 1, pp. 111-116